Vision Failure Means End Of The Road For Oxurion

20 Nov 2023

Disappointing data from a trial of the last remaining drug in its pipeline means that the Belgium group formerly known as ThromboGenics is closing its doors after more than 30 years.

Once regarded as one of Europe's most promising biotechs, the curtain has fallen on Oxurion NV after the last diabetic eye disease drug in its pipeline failed a mid-stage trial.

The Belgian ophthalmology specialist said on 20 November it had "decided to take the necessary steps to file for bankruptcy"...